The interaction between antioxidant status and cervical cancer: a case control study

Senem Demirci¹, Zeynep Ozsaran¹, Handan Ak Celik², Arif Bulent Aras¹, and Hikmet Hakan Aydin²

¹Department of Radiation Oncology, ²Department of Medical Biochemistry, Ege University Faculty of Medicine, Bornova, Izmir, Turkey

ABSTRACT

Aims and background. To compare the antioxidant status of cervical cancer patients with healthy controls and to assess the antioxidant levels before and after radiotherapy or radiochemotherapy.

Methods and study design. Antioxidant levels (glutathione, glutathione peroxidase, superoxide dismutase, and malondialdehyde) were measured in 35 patients with cervical cancer and 35 age-matched healthy controls. Blood samples were collected twice (before and after treatment) from cervical cancer patients and once from healthy control subjects.

Results. In the patient group, pre-radiotherapy glutathione and glutathione peroxidase levels were significantly lower (P < 0.01 and P < 0.0001, respectively) than the control group. Pre-radiotherapy levels of superoxide dismutase were significantly higher in cancer patients (P < 0.01). In general, no difference was observed between pre- and post-radiotherapy antioxidant levels in cancer patients. However, when post-radiotherapy glutathione levels were analyzed, patients who did not respond to treatment had significantly higher levels than those who did respond (P < 0.01).

Conclusions. Levels of antioxidants significantly differed between the patients with cervical cancer and the controls, and no change in antioxidant levels was observed after treatment. Moreover, further studies evaluating the predictive value of glutathione levels on treatment response are warranted.

Key words: antioxidant status, radiation, uterine cervical neoplasms.

Acknowledgments: The study was supported by Ege University Scientific Research Board with project number of "2004-TIP-007". We gratefully thank the clinical nurses from the Department of Radiation Oncology — Oya Bildik, Emine Kaya and Figan Gülersoy for their assistance. We also thank Nurten Cetiner, Asil Gonul, Tayyibe Yeni, Nurdan Guldiken and Ozge Tokul, from AREL (Research and Education Laboratory), Ege University School of Medicine, for their technical assistance.

Conflicts of interest notification: None.

Financial disclosures: None.

Correspondence to: Senem Demirci, MD, Ege University Faculty of Medicine, Department of Radiation Oncology, Bornova, 35100, Izmir, Turkey. Tel +90-232-3904476; fax +90-232-3884294; e-mail senem.demirci@ege.edu.tr

Received September 17, 2010; accepted January 17, 2011.